Inclusion complexes of bendamustine with β-CD, HP-β-CD and Epi-β-CD: in-vitro and in-vivo evaluation. (2nd December 2015)
- Record Type:
- Journal Article
- Title:
- Inclusion complexes of bendamustine with β-CD, HP-β-CD and Epi-β-CD: in-vitro and in-vivo evaluation. (2nd December 2015)
- Main Title:
- Inclusion complexes of bendamustine with β-CD, HP-β-CD and Epi-β-CD: in-vitro and in-vivo evaluation
- Authors:
- Gidwani, Bina
Vyas, Amber - Abstract:
- Abstract: The objective of the present work was to investigate the inclusion behavior of bendamustine (BM) with β-cyclodextrin and its hydrophilic derivatives (HP-β-CD and Epi-β-CD) for the enhancement of aqueous solubility, dissolution and bioavailability. The supramolecular binary complexes were prepared by three different methods, viz. physical mixture (PM), kneading (KND) and co-evaporation (COE). Phase-solubility study revealed the higher solubilizing and complexing ability of polymerized cyclodextrin ( K s = 645 M −1 ) than parent cyclodextrin ( K s = 43 M −1 ) and chemically derived cyclodextrin ( K s = 100 M −1 ). Meanwhile, the solubility of BM was significantly enhanced in phosphate buffer of pH 6.8, which was 24.5 folds greater compared with the phosphate buffer pH 4.5 and four times greater than aqueous medium. The dissolution efficiency was found to be highest for BM: Epi-β-CD complex (87%) compared to BM: HP-β-CD complex (84%), BM: β-CD (79%) and pure drug (20%). In-vivo pharmacokinetic study revealed that the bioavailability of BM was enhanced 2.55 times on complexation with Epi-β-CD using KND method. The t 1/2 of BM was increased from 34.2 min to approximately 75.7 min, allowing the absorption for longer time. The order of increase in solubility, dissolution and bioavailability of BM was KND > COE > PM > pure drug. Thus, the strategy of host–guest inclusion was very effective and could be successfully used in the development of suitable pharmaceuticalAbstract: The objective of the present work was to investigate the inclusion behavior of bendamustine (BM) with β-cyclodextrin and its hydrophilic derivatives (HP-β-CD and Epi-β-CD) for the enhancement of aqueous solubility, dissolution and bioavailability. The supramolecular binary complexes were prepared by three different methods, viz. physical mixture (PM), kneading (KND) and co-evaporation (COE). Phase-solubility study revealed the higher solubilizing and complexing ability of polymerized cyclodextrin ( K s = 645 M −1 ) than parent cyclodextrin ( K s = 43 M −1 ) and chemically derived cyclodextrin ( K s = 100 M −1 ). Meanwhile, the solubility of BM was significantly enhanced in phosphate buffer of pH 6.8, which was 24.5 folds greater compared with the phosphate buffer pH 4.5 and four times greater than aqueous medium. The dissolution efficiency was found to be highest for BM: Epi-β-CD complex (87%) compared to BM: HP-β-CD complex (84%), BM: β-CD (79%) and pure drug (20%). In-vivo pharmacokinetic study revealed that the bioavailability of BM was enhanced 2.55 times on complexation with Epi-β-CD using KND method. The t 1/2 of BM was increased from 34.2 min to approximately 75.7 min, allowing the absorption for longer time. The order of increase in solubility, dissolution and bioavailability of BM was KND > COE > PM > pure drug. Thus, the strategy of host–guest inclusion was very effective and could be successfully used in the development of suitable pharmaceutical dosage form with enhanced therapeutic activity. … (more)
- Is Part Of:
- Drug development and industrial pharmacy. Volume 41:Number 12(2015:Dec.)
- Journal:
- Drug development and industrial pharmacy
- Issue:
- Volume 41:Number 12(2015:Dec.)
- Issue Display:
- Volume 41, Issue 12 (2015)
- Year:
- 2015
- Volume:
- 41
- Issue:
- 12
- Issue Sort Value:
- 2015-0041-0012-0000
- Page Start:
- 1978
- Page End:
- 1988
- Publication Date:
- 2015-12-02
- Subjects:
- Bendamustine -- complexation -- dissolution -- phase solubility -- polymerized cyclodextrin
Pharmaceutical chemistry -- Periodicals
Pharmaceutical industry -- Periodicals
Drug Industry -- Periodicals
Technology, Pharmaceutical -- Periodicals
615.05 - Journal URLs:
- http://informahealthcare.com/loi/ddi ↗
http://informahealthcare.com ↗ - DOI:
- 10.3109/03639045.2015.1027217 ↗
- Languages:
- English
- ISSNs:
- 0363-9045
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3629.116000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11399.xml